The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?
Open accessAbstract
Nanotechnology is the design and assembly of submicroscopic devices called nanoparticles, which are 1–100 nm in diameter. Nanomedicine is the application of nanotechnology for the diagnosis and treatment of human disease. Disease-specific receptors on the surface of cells provide useful targets for nanoparticles. Because nanoparticles can be engineered from components that (1) recognize disease at the cellular level, (2) are visible on imaging studies, and (3) deliver therapeutic compounds, nanotechnology is well suited for the diagnosis and treatment of a variety of diseases. Nanotechnology will enable earlier detection and treatment of diseases that are best treated in their initial stages, such as cancer. Advances in nanotechnology will also spur the discovery of new methods for delivery of therapeutic compounds, including genes and proteins, to diseased tissue. A myriad of nanostructured drugs with effective site-targeting can be developed by combining a diverse selection of targeting, diagnostic, and therapeutic components. Incorporating immune target specificity with nanostructures introduces a new type of treatment modality, nano-immunochemotherapy, for patients with cancer. In this review, we will discuss the development and potential applications of nanoscale platforms in medical diagnosis and treatment. To impact the care of patients with neurological diseases, advances in nanotechnology will require accelerated translation to the fields of brain mapping, CNS imaging, and nanoneurosurgery. Advances in nanoplatform, nano-imaging, and nano-drug delivery will drive the future development of nanomedicine, personalized medicine, and targeted therapy. We believe that the formation of a science, technology, medicine law–healthcare policy (STML) hub/center, which encourages collaboration among universities, medical centers, US government, industry, patient advocacy groups, charitable foundations, and philanthropists, could significantly facilitate such advancements and contribute to the translation of nanotechnology across medical disciplines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Wang, Y.-X. J., Hussain, S. M., & Krestin, G. P. (2001) · European Radiology · doi:10.1007/s003300100908 · Cited by 1,381
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
de Vries, I. J. M., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J. G., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1154 · Cited by 821
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592
Arbab, A. S., Yocum, G. T., Rad, A. M., Khakoo, A. Y., Fellowes, V., Read, E. J., & Frank, J. A. (2005) · NMR in Biomedicine · doi:10.1002/nbm.991 · Cited by 297
Neuwelt, E. A., Hamilton, B. E., Varallyay, C. G., Rooney, W. R., Edelman, R. D., Jacobs, P. M., & Watnick, S. G. (2009) · Kidney International · doi:10.1038/ki.2008.496 · Cited by 267
Sanchez, V. C., Pietruska, J. R., Miselis, N. R., Hurt, R. H., & Kane, A. B. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.41 · Cited by 186
Magnetic tagging of therapeutic cells for MRI
Budde, M. D., & Frank, J. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.053546 · Cited by 78
Cited by
Magnetic Nanoparticles: Surface Effects and Properties Related to Biomedicine Applications
Issa, B., Obaidat, I., Albiss, B., & Haik, Y. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121266 · Cited by 1,245
Duan, X., & Li, Y. (2013) · Small · doi:10.1002/smll.201201390 · Cited by 926
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Self-citationPolymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 485
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Metadata
- Authors
- Kateb, B., Chiu, K., Black, K. L., Yamamoto, V., Khalsa, B., Ljubimova, J. Y., Ding, H., Patil, R., Portilla-Arias, J. A., Modo, M., Moore, D. F., Farahani, K., Okun, M. S., Prakash, N., Neman, J., Ahdoot, D., Grundfest, W., Nikzad, S., & Heiss, J. D.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 54
- Pages
- S106-S124
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2039581700
- Cited by
- 188
- References
- 10
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? https://app.cochat.ai/papers/10.1016/j.neuroimage.2010.01.105
- The paper
- Kateb, B., Chiu, K., Black, K. L., Yamamoto, V., Khalsa, B., Ljubimova, J. Y., Ding, H., Patil, R., Portilla-Arias, J. A., Modo, M., Moore, D. F., Farahani, K., Okun, M. S., Prakash, N., Neman, J., Ahdoot, D., Grundfest, W., Nikzad, S., & Heiss, J. D. (2011). Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? NeuroImage. https://doi.org/10.1016/j.neuroimage.2010.01.105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.